Comphya raises CHF 7.5 million for its neurostimulation therapy to treat erectile dysfunction

Vaud-based medtech Comphya strengthens its clinical pipeline with fresh capital and prepares for pivotal trials in the United States.

Comphya SA, a Lausanne-based medtech start-up developing a first-of-its-kind neurostimulation therapy for erectile dysfunction (ED), has announced the successful closing of an oversubscribed Series A financing round, bringing its total equity raised to CHF 7.5 million (USD 8.4 million).

The company is developing CaverSTIM, the first implantable neuromodulator aimed at restoring erectile function in patients unresponsive to standard treatments such as oral medication. This includes men recovering from prostate cancer surgery, a group that currently lacks effective therapeutic alternatives.

Earlier in 2025, Comphya secured CHF 4.35 million in the first tranche of its Series A to support its first-in-human clinical trial in Australia. Patients undergoing robotic-assisted prostatectomy were implanted with the CaverSTIM system, and early results presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas showed promising safety and efficacy. Most participants maintained satisfactory erectile function postoperatively without additional therapies, with no adverse events reported.

The additional funds will allow Comphya to expand the Australian trial and launch a pilot study in the United States, following FDA Investigational Device Exemption (IDE) approval. The U.S. study is already underway at Johns Hopkins and will inform the design of a pivotal clinical trial planned for 2026. The company expects to raise a Series B round to support that next phase.

From local innovation to global execution

Founded as a spin-off from EPFL, Comphya has emerged as a notable player within Western Switzerland’s growing medtech sector, previously featured among regional innovators conducting human trials. The latest investment marks another step in its transition from early-stage innovation to global clinical execution.

The Series A round also marks a leadership transition, with the appointment of industry veteran Pim van Wesel as CEO in May 2025. “We’re entering an important new chapter,” van Wesel said in the company’s press release. “With investor support, we’re well positioned to bring this much-needed therapy to men affected by erectile dysfunction after prostate cancer.”